Fidaxomicin 200mg, 40mg/5ml Suppliers & Bulk Manufacturers

Available Forms: Tablets / Oral suspension

Available Strengths: 200mg, 40mg/5ml

Reference Brands: Dificid (USA), Dificlir (EU/UK)

Category: Antibiotics

Fidaxomicin is a narrow-spectrum macrocyclic antibiotic used only for Clostridioides difficile infection. It stays in the gut and spares most normal gut bacteria, so C. difficile comes back less often than after vancomycin. It is supplied as 200 mg tablets and an oral suspension; reference brands are Dificid (US) and Dificlir (EU). Patent status differs by country, so we confirm what can lawfully be supplied to your destination before quoting.

Product Description:

Fidaxomicin is a macrocyclic antibiotic used exclusively for Clostridioides difficile infection, and its value rests on what it does not do. It is minimally absorbed, remaining in the gut lumen where the infection is, and it has an unusually narrow spectrum that spares the anaerobic gut flora. Because that flora is what normally resists C. difficile colonisation, preserving it substantially reduces recurrence — the principal problem in this infection, where a quarter or more of patients relapse after treatment with vancomycin or metronidazole.

It is supplied as 200 mg tablets and as oral suspension at 40 mg per mL for paediatric use.

Sourcing notes. Fidaxomicin is expensive relative to oral vancomycin, and tenders comparing unit price alone will always favour vancomycin. The economic case rests on avoided recurrence and avoided readmission, so establish which basis the buyer is evaluating on. Guidelines in several jurisdictions now recommend fidaxomicin as first-line, which is shifting that calculation. Patent and exclusivity position varies by territory — verify freedom to operate in the destination market rather than assuming genericisability. WHO classifies fidaxomicin under Watch.